- Home
- DVAX vs SSII Comparison
DVAX vs SSII Comparison
Compare DVAX & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- SSII
- Stock Information
- Founded
- DVAX 1996
- SSII N/A
- Country
- DVAX United States
- SSII India
- Employees
- DVAX N/A
- SSII N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- SSII
- Sector
- DVAX Health Care
- SSII
- Exchange
- DVAX Nasdaq
- SSII Nasdaq
- Market Cap
- DVAX 1.2B
- SSII 1.4B
- IPO Year
- DVAX 2004
- SSII N/A
- Fundamental
- Price
- DVAX $11.21
- SSII $6.52
- Analyst Decision
- DVAX Buy
- SSII
- Analyst Count
- DVAX 4
- SSII 0
- Target Price
- DVAX $26.50
- SSII N/A
- AVG Volume (30 Days)
- DVAX 1.7M
- SSII 86.9K
- Earning Date
- DVAX 11-05-2025
- SSII 10-28-2025
- Dividend Yield
- DVAX N/A
- SSII N/A
- EPS Growth
- DVAX N/A
- SSII N/A
- EPS
- DVAX N/A
- SSII N/A
- Revenue
- DVAX $330,514,000.00
- SSII $36,066,457.00
- Revenue This Year
- DVAX $23.23
- SSII N/A
- Revenue Next Year
- DVAX $16.57
- SSII N/A
- P/E Ratio
- DVAX N/A
- SSII N/A
- Revenue Growth
- DVAX 26.73
- SSII 158.36
- 52 Week Low
- DVAX $9.20
- SSII $2.48
- 52 Week High
- DVAX $14.63
- SSII $22.42
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- SSII 38.37
- Support Level
- DVAX $10.97
- SSII $6.12
- Resistance Level
- DVAX $11.43
- SSII $7.13
- Average True Range (ATR)
- DVAX 0.36
- SSII 0.59
- MACD
- DVAX 0.07
- SSII -0.22
- Stochastic Oscillator
- DVAX 86.42
- SSII 15.91
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.